ERBB2 and breast carcinoma: In a double-blind, randomized phase III trial comparing the safety and efficacy of pertuzumab with trastuzumab and docetaxel, the median progression-free survival was 18.5 months; while the overall survival and objective response rate (80.2%) was higher than the observed placebo group, leading the European Medicines Agency to also approve pertuzumab for treating HER2-positive breast cancer [36].